GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » ROE % Adjusted to Book Value

CLVSF (CellaVision AB) ROE % Adjusted to Book Value : 2.03% (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB ROE % Adjusted to Book Value?

CellaVision AB's ROE % for the quarter that ended in Sep. 2024 was 16.72%. CellaVision AB's PB Ratio for the quarter that ended in Sep. 2024 was 8.23. CellaVision AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 2.03%.


CellaVision AB ROE % Adjusted to Book Value Historical Data

The historical data trend for CellaVision AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB ROE % Adjusted to Book Value Chart

CellaVision AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 1.70 1.81 2.16 3.38

CellaVision AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.35 5.26 2.32 2.99 2.03

Competitive Comparison of CellaVision AB's ROE % Adjusted to Book Value

For the Medical Devices subindustry, CellaVision AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CellaVision AB's ROE % Adjusted to Book Value falls into.



CellaVision AB ROE % Adjusted to Book Value Calculation

CellaVision AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=19.30% / 5.71
=3.38%

CellaVision AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=16.72% / 8.23
=2.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellaVision AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CellaVision AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.

CellaVision AB Headlines